Advertisement

An updated systematic review and meta-analysis about the safety and efficacy of infliximab biosimilar, CT-P13, for patients with inflammatory bowel disease

  • Mahmoud Ahmed EbadaEmail author
  • Abdelmagid M. Elmatboly
  • Ahmed Said Ali
  • Ahmed Mohamed Ibrahim
  • Notila Fayed
  • Ahmed Faisal Faisal
  • Souad Alkanj
Review
  • 82 Downloads

Abstract

Objective

We aimed to evaluate the efficacy and safety of infliximab biosimilar, CT-P13, for patients with inflammatory bowel disease.

Methods

We searched PubMed, Scopus, Ovid, and Web of Science for relevant clinical trials discussing CT-P31 administration for IBD patients either naïve to biological therapy or switched from IFX therapy. Data of the rates of clinical response, clinical remission, and adverse events were extracted and pooled in a random effect model meta-analysis using CMA version 2.

Results

Thirty-two studies with a total of 3464 IBD patients treated with CT-P13 were identified. The pooled rates of clinical response among Crohn’s disease (CD) and ulcerative colitis (UC) at 8–14 weeks were 0.81 (95% CI = 0.72 to 0.87) and 0.68 (95% CI = 0.63 to 0.72), respectively, and at 48–63 weeks were 0.69 (95% CI = 0.48 to 0.85) and 0.54 (95% CI = 0.45 to 0.63) respectively. After switching from IFX to CT-P13, the pooled rates of sustained clinical response among CD and UC at 30–32 weeks were 0.84 (95% CI = 0.57 to 0.96) and 0.96 (95% CI = 0.58 to 0.99), respectively, and at 48–63 weeks were 0.51 (95% CI = 0.22 to 0.79) and 0.83 (95% CI = 0.19 to 0.99) respectively. Moreover, adverse events were reported (CD = 0.10, 95% CI 0.04 to 0.22; UC = 0.18, 95% CI 0.05 to 0.15).

Conclusion

CT-P13 is effective and well tolerated in short and long-term periods. Switching to CT-P13 is recommended for the management of IBD.

Keywords

CT-P13 Infliximab IFX Inflammatory bowel diseases Meta-analysis Systematic review 

Notes

Acknowledgments

Special thanks are to be directed to the Medical Research Group of Egypt (MRGE) members, especially Dr. Ahmed Negida, for his support while revising this manuscript.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Supplementary material

384_2019_3354_MOESM1_ESM.pdf (291 kb)
Appendix S1 a shows a forest plot of mucosal healing in naïve UC patients. b shows the risk of bias summary according to the Cochrane Risk of Bias assessment tool (PDF 291 kb)

References

  1. 1.
    Keil R, Wasserbauer M, Zádorová Z, Hajer J, Drastich P, Wohl P, Beneš M, Bojková M, Svoboda P, Konečný M, Falt P, Vaňásek T, Pešta M, Pešek F, Bouchner L, Koželuhová J, Novotný A, Bartůsková L, Špičák J (2016) Clinical monitoring: infliximab biosimilar CT-P13 in the treatment of Crohn’s disease and ulcerative colitis. Scand J Gastroenterol 51:1062–1068.  https://doi.org/10.3109/00365521.2016.1149883 CrossRefGoogle Scholar
  2. 2.
    Rutgeerts P, Assche GVAN, Vermeire S (2006) Review article : infliximab therapy for inflammatory bowel disease – seven years on:451–463.  https://doi.org/10.1111/j.1365-2036.2006.02786.x
  3. 3.
    Argüelles-Arias F, Guerra Veloz MF, Perea Amarillo R, Vilches-Arenas A, Castro Laria L, Maldonado Pérez B, Chaaro D, Benítez Roldán A, Merino V, Ramírez G, Caunedo Álvarez A, Romero Gómez M (2017) Effectiveness and safety of CT-P13 (biosimilar infliximab) in patients with inflammatory bowel disease in real life at 6 months. Dig Dis Sci 62:1305–1312.  https://doi.org/10.1007/s10620-017-4511-4 CrossRefGoogle Scholar
  4. 4.
    Jahnsen J, Detlie TE, Vatn S, Ricanek P (2015) Biosimilar infliximab (CT-P13) in the treatment of inflammatory bowel disease: a Norwegian observational study. Expert Rev Gastroenterol Hepatol 9:S45–S52.  https://doi.org/10.1586/17474124.2015.1091308 CrossRefGoogle Scholar
  5. 5.
    Jung YS, Il PD, Kim YH et al (2015) Efficacy and safety of CT-P13, a biosimilar of infliximab, in patients with inflammatory bowel disease: a retrospective multicenter study. J Gastroenterol Hepatol 30:1705–1712.  https://doi.org/10.1111/jgh.12997 CrossRefGoogle Scholar
  6. 6.
    Alten R, Batko B, Hala T et al (2019) Randomised, double-blind, phase III study comparing the infliximab biosimilar, PF-06438179/GP1111, with reference infliximab: efficacy, safety and immunogenicity from week 30 to week 54. RMD Open 5:e000876.  https://doi.org/10.1136/rmdopen-2018-000876 CrossRefGoogle Scholar
  7. 7.
    Cohen S, Pablos JL, Pavelka K et al (2019) An open-label extension study to demonstrate long-term safety and efficacy of ABP 501 in patients with rheumatoid arthritis, vol 3, pp 1–10Google Scholar
  8. 8.
    Cohen S, Genovese MC, Choy E, Perez-Ruiz F, Matsumoto A, Pavelka K, Pablos JL, Rizzo W, Hrycaj P, Zhang N, Shergy W, Kaur P (2017) Efficacy and safety of the biosimilar ABP 501 compared with adalimumab in patients with moderate to severe rheumatoid arthritis: a randomised, double-blind, phase III equivalence study. Ann Rheum Dis 76:1679–1687.  https://doi.org/10.1136/annrheumdis-2016-210459 CrossRefGoogle Scholar
  9. 9.
    (2017) Curr Rheumatol 2007. 138160Google Scholar
  10. 10.
    Popova EV, Boyko AN, Bykova OV, Nankina IG, Batysheva TT (2016) Experience of application of Russian biosimilar of interferon beta-1b for treatment of pediatric multiple sclerosis. Zhurnal Nevrol i Psihiatr Im SS Korsakova 116:73–75.  https://doi.org/10.17116/JNEVRO20161166173-75 CrossRefGoogle Scholar
  11. 11.
    Komaki Y, Yamada A, Komaki F, Micic D, Ido A, Sakuraba A (2017) Systematic review with meta-analysis: the efficacy and safety of CT-P13, a biosimilar of anti-tumour necrosis factor-α agent (infliximab), in inflammatory bowel diseases. Aliment Pharmacol Ther 45:1043–1057.  https://doi.org/10.1111/apt.13990 CrossRefGoogle Scholar
  12. 12.
    Shamseer L, Moher D, Clarke M et al (2015) Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ 350:g7647CrossRefGoogle Scholar
  13. 13.
    Higgins JP, Green S (2008) Cochrane handbook for systematic reviews of interventions: Cochrane book series. Cochrane Handb Syst rev Interv Cochrane B Ser 1–649.  https://doi.org/10.1002/9780470712184
  14. 14.
    Reviews C, Reviews C, Library TC Cochrane handbook for systematic reviews of interventions chapter 1: introduction UNDER CONSTRUCTION - PLEASE DO NOT USE Key points. 1–8Google Scholar
  15. 15.
    Adequate CD, This C CODING MANUAL FOR CASE-CONTROL STUDIESGoogle Scholar
  16. 16.
    Raj R, Mikkonen ED, Siironen J et al (2015) Alcohol and mortality after moderate to severe traumatic brain injury: a meta-analysis of observational studies. 1–9.  https://doi.org/10.3171/2015.4.JNS141746 Google Scholar
  17. 17.
    Zhang X (2015) Prognostic role of neutrophil to lymphocyte ratio in lung cancers: a meta-analysis including, pp 2731–2738Google Scholar
  18. 18.
    Blair HA, Deeks ED (2016) Infliximab biosimilar (CT-P13; infliximab-dyyb): a review in autoimmune inflammatory diseases. BioDrugs 30:469–480.  https://doi.org/10.1007/s40259-016-0193-2 CrossRefGoogle Scholar
  19. 19.
    Pereira TV, Patsopoulos NA, Salanti G, Ioannidis JPA (2010) Critical interpretation of Cochran’s Q test depends on power and prior assumptions about heterogeneity. Res Synth Methods 1:149–161.  https://doi.org/10.1002/jrsm.13 CrossRefGoogle Scholar
  20. 20.
    Park SH, Kim YH, Lee JH, Kwon HJ, Lee SH, Park DI, Kim HK, Cheon JH, Im JP, Kim YS, Lee SY, Lee SJ (2015) Post-marketing study of biosimilar infliximab (CT-P13) to evaluate its safety and efficacy in Korea. Expert Rev Gastroenterol Hepatol 9:S35–S44.  https://doi.org/10.1586/17474124.2015.1091309 CrossRefGoogle Scholar
  21. 21.
    Hruba V, Bortlik M, Lukas Jr. M, et al (2017) Infliximab biosimilar (Remsima™) in therapy of inflammatory bowel diseases patients: experience from one tertiary inflammatory bowel diseases centre. Dig Dis 35:91–100.  https://doi.org/10.1159/000453343
  22. 22.
    Smits LJT, Derikx LAAP, de Jong DJ, Boshuizen RS, van Esch AAJ, Drenth JPH, Hoentjen F (2016) Clinical outcomes following a switch from Remicade® to the biosimilar CT-P13 in inflammatory bowel disease patients: a prospective observational cohort study. J Crohn's Colitis 10:1287–1293.  https://doi.org/10.1093/ecco-jcc/jjw087 CrossRefGoogle Scholar
  23. 23.
    Veloz MFG, Morón JMV, Jiménez MB et al (2018) Switching from reference infliximab to CT-P13 in patients with inflammatory bowel disease: results of a multicenter study after 12 months. Rev Esp Enfermedades Dig 110:564–570.  https://doi.org/10.17235/REED.2018.5368/2017 CrossRefGoogle Scholar
  24. 24.
    Ratnakumaran R, To N, Gracie DJ et al (2018) Efficacy and tolerability of initiating , or switching to , infliximab biosimilar CT-P13 in inflammatory bowel disease ( IBD ): a large single-Centre experience. Scand J Gastroenterol 0:1–8.  https://doi.org/10.1080/00365521.2018.1464203 Google Scholar
  25. 25.
    Komaki Y, Yamada A, Komaki F, et al (2017) Alimentary pharmacology and therapeutics systematic review with meta-analysis : the efficacy and safety of CT-P13 , a biosimilar of anti-tumour necrosis factor- a agent (infliximab), in in flammatory bowel diseases. 1–15.  https://doi.org/10.1111/apt.13990
  26. 26.
    Midtgard IP, Lundin KEA, Dvergsnes K et al (2017) Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial. Lancet 389:2304–2316.  https://doi.org/10.1016/s0140-6736(17)30068-5 CrossRefGoogle Scholar
  27. 27.
    Pesegova M, Ye BD, Lee SJ, et al (2018) 814 - Phase Iii randomized controlled trial to compare biosimilar infliximab (CT-P13) with innovator infliximab in patients with active Crohn’s disease: 1-year maintenance and switching results. Gastroenterology 154:S-167-S-168.  https://doi.org/10.1016/s0016-5085(18)30972-7
  28. 28.
    Ratnakumaran R, To N, Gracie DJ et al (2018) Efficacy and tolerability of initiating, or switching to, infliximab biosimilar CT-P13 in inflammatory bowel disease (IBD): a large single-centre experience. Scand J Gastroenterol 53:700–707.  https://doi.org/10.1080/00365521.2018.1464203 CrossRefGoogle Scholar
  29. 29.
    Noble CL, Watson EF, Merchant LM et al (2018) Implementation of CT-P13 via a managed switch programme in Crohn’s disease: 12-month real-world outcomes. Dig Dis Sci 64:1660–1667.  https://doi.org/10.1007/s10620-018-5406-8 Google Scholar
  30. 30.
    Beloso C, Souto J, Fábregat M, Romanelli G, Javiel G MA (2018) World journal of. World J Diabetes 9:157–164.  https://doi.org/10.5321/wjs.v2.i3.40
  31. 31.
    Arguëlles-Arias F, Guerra Veloz MF, Perea Amarillo R et al (2017) Switching from reference infliximab to CT-P13 in patients with inflammatory bowel disease: 12 months results. Eur J Gastroenterol Hepatol 29:1290–1295.  https://doi.org/10.1097/MEG.0000000000000953 CrossRefGoogle Scholar
  32. 32.
    Lim YJ, Kang HW, Lee SE et al (2014) Clinical experience of the use of CT-P13, a biosimilar to infliximab in patients with inflammatory bowel disease: a case series. Dig Dis Sci 60:951–956.  https://doi.org/10.1007/s10620-014-3392-z Google Scholar
  33. 33.
    Sieczkowska-Golub J, Meglicka M, Plocek A, Banaszkiewicz A, Jarzębicka D, Toporowska-Kowalska E, Gawronska A, Oracz G, Kierkus J (2017) Induction therapy with biosimilar infliximab in children with Crohn disease. J Pediatr Gastroenterol Nutr 65:285–288.  https://doi.org/10.1097/MPG.0000000000001643 CrossRefGoogle Scholar
  34. 34.
    Sieczkowska J, Banaszkiewicz A, Plocek A, Jarzebicka D P430 Assessment of safety and efficacy of biosimilar infliximab in children with Crohn disease : a preliminary report . P429 Influence of Disease Course on Therapeutic Effect of IFX in Crohn ’ s disease P431 Serology panel for prediction relapse after dis. 431Google Scholar
  35. 35.
    Gecse KB, Lovász BD, Farkas K et al (2016) Efficacy and Safety of the Biosimilar Infliximab CT-P13 Treatment in Inflammatory Bowel Diseases: A Prospective, Multicentre, Nationwide Cohort. J Crohns Colitis 10:133–140.  https://doi.org/10.1093/ecco-jcc/jjv220 CrossRefGoogle Scholar
  36. 36.
    Hlavaty T, Krajcovicova A, Sturdik I et al (2016) Biosimilar infl iximab CT-Pwy treatment in patients with infl am matory bowel diseases - a one-year, single-centre retrospective study. Gastroenterol a Hepatol 70:27–36.  https://doi.org/10.14735/amgh201627 CrossRefGoogle Scholar
  37. 37.
    Nagy F, Farkas K, Rutka M, Ba A (2015) Efficacy of the new infliximab biosimilar CT-P13 induction therapy in Crohn ’ s disease and ulcerative colitis - experiences from a single center. 1–6.  https://doi.org/10.1517/14712598.2015.1064893
  38. 38.
  39. 39.
    Hyoung YK, Moon H (2015) Clinical experience of the use of CT-P13 , a biosimilar to infliximab in patients with inflammatory bowel disease : a case series. Dig Dis Sci 951–956.  https://doi.org/10.1007/s10620-014-3392-z
  40. 40.
    Gonczi L, Gecse KB, Vegh Z, et al (2017) Long-term efficacy, safety, and immunogenicity of biosimilar infliximab after one year in a prospective Nationwide Cohort. 0:1–8.  https://doi.org/10.1097/MIB.0000000000001237
  41. 41.
    (2015) P329 Infliximab biosimilar in the treatment of inflammatory bowel disease : a Japanese single- cohort observational study P331 Allopurinol and azathioprine co-therapy or thioguanine dose splitting : shifting the shunters in the mercaptopurine pathway in a. 330Google Scholar
  42. 42.
    Sanchez SDS, Wan H, Streck P, et al Pooled safety analysis of long-term , once-daily multimatrix mesalazine use P540 Efficacy and safety of infliximab ’ s biosimilar ( REMSIMA ) for IBD P539 Outcome of acute severe ulcerative colitis in patients previously exposed to immunosoppressive thera. 349–350Google Scholar
  43. 43.
    Ostrava H, Republic C, Colentina CH (2017) P420 Effectiveness and safety of biosimilar infliximab ( remsima ) in a real-life setting in 84 patients with Crohn ’ s disease and ulcerative colitis P419 Frequency of inadequate response to anti- tumour necrosis factor therapy in patients with ulcerativ. 51:70–71Google Scholar
  44. 44.
    Danese S, Neurath M, Kopon A, et al AGA Abstracts AGA Abstracts AGA Abstracts S-168. Gastroenterology 154:S-167–S-168.  https://doi.org/10.1016/S0016-5085(18)30972-7
  45. 45.
    Farkas K, Rutka M, Bálint A et al (2015) Efficacy of the new infliximab biosimilar CT-P13 induction therapy in Crohn’s disease and ulcerative colitis – experiences from a single center. Expert Opin Biol Ther 15:1257–1262.  https://doi.org/10.1517/14712598.2015.1064893 CrossRefGoogle Scholar
  46. 46.
    Bálint A, Rutka M, Kolar M et al (2018) Expert Opinion on Biological Therapy Infliximab biosimilar CT-P13 therapy is effective in maintaining endoscopic remission in ulcerative colitis – results from multicenter observational cohort remission in ulcerative colitis – results from multicenter obs. Expert Opin Biol Ther 18:1181–1187.  https://doi.org/10.1080/14712598.2018.1530758 CrossRefGoogle Scholar
  47. 47.
    Argüelles-arias F, Fernanda M, Veloz G, et al (2017) Switching from reference in fliximab to CT-P13 in patients with in flammatory bowel disease : 12 months results. 1–6.  https://doi.org/10.1097/MEG.0000000000000953
  48. 48.
    Bergqvist V, Kadivar M, Molin D, et al (2018) Switching from originator infliximab to the biosimilar CT-P13 in 313 patients with inflammatory bowel disease. 1–13.  https://doi.org/10.1177/1756284818801244
  49. 49.
    (2016) P337 Switching from originator infliximab to CT-P13 : single-centre experience from the UK P339 Application of Bayesian modelling with infliximab to determine optimal patient-specific regimens P338 Long-term complications in patients with fistulising Croh. 13–14Google Scholar
  50. 50.
    Plevris N, Jones GR, Jenkinson PW et al (2018) Implementation of CT - P13 via a Managed Switch Programme in Crohn ’ s Disease : 12 - Month Real - World Outcomes. Dig Dis Sci.  https://doi.org/10.1007/s10620-018-5406-8
  51. 51.
    Gastroenterol WJ (2018) World Journal of. 9327Google Scholar
  52. 52.
    Sieczkowska J, Jarzębicka D, Banaszkiewicz A et al (2016) Switching between infliximab originator and biosimilar in paediatric patients with inflammatory bowel disease. Preliminary observations. J Crohns Colitis 10:127–132.  https://doi.org/10.1093/ecco-jcc/jjv233 CrossRefGoogle Scholar
  53. 53.
    Buer LCT, Moum BA, Cvancarova M et al (2017) Switching from Remicade® to Remsima® is well tolerated and feasible: a prospective, open-label study. J Crohns Colitis 11:297–304.  https://doi.org/10.1093/ecco-jcc/jjw166 CrossRefGoogle Scholar
  54. 54.
    Olsen IC, Goll GL, Lorentzen M, et al (2017) Articles Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week , randomised ,. 6736:.  https://doi.org/10.1016/S0140-6736(17)30068-5
  55. 55.
    (2018) Efficacy , safety and economic impact of the switch to biosimilar of infliximab in inflammatory bowel disease patients in clinical practice : results of one The long-term efficacy of adalimumab on Crohn ’ s disease comorbid with perianal lesions and poor. 2961572Google Scholar
  56. 56.
    Nasuno M, Tanaka H, Miyakawa M, et al (2018) Short-term outcomes of adalimumab for patients with Crohn ’ s disease and associated prognostic factors : a multicentre retrospective cohort study Unchanged infliximab serum concentrations after switching from the reference infliximab to the biosimilar CT. 2961608Google Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Faculty of MedicineZagazig UniversityZagazigEgypt
  2. 2.Medical Research Group of Egypt (MRGE)ZagazigEgypt
  3. 3.Zagazig University HospitalsZagazig UniversityZagazigEgypt
  4. 4.Faculty of MedicineAl-Azhar UniversityCairoEgypt

Personalised recommendations